• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»PNPLA3 mutation

What Madrigal Pharmaceuticals, Inc.’s siRNA deal signals for the future of MASH treatment

By Soujanya Ravi on May 5, 2026   Pharma & Biotech  

What Madrigal Pharmaceuticals, Inc.’s siRNA deal signals for the future of MASH treatment

Can Madrigal Pharmaceuticals, Inc. reshape MASH treatment with ARO-PNPLA3? Discover what this precision strategy means for the future.

Recent Posts

  • Phillips Medisize targets formulation-device risk as inhaled therapies grow more complex
  • Could TRexBio’s Treg bet crack the next big frontier in atopic dermatitis?
  • Fujifilm’s ELUXEO 8000 and EG-840TP pairing raises the bar in interventional endoscopy
  • Why PALISADE-4 is a high-stakes test for Vistagen’s nose-to-brain anxiety drug strategy
  • Can PharmaJet’s needle-free Tropis system help Nigeria close its polio gap?
  • Why Sensus Healthcare’s SkinCure resolution matters for superficial radiotherapy growth
  • Why Encompass Health is betting on a fast-growing Texas suburb before rivals crowd in
  • What Saban Community Clinic’s Crenshaw project reveals about urban healthcare deserts
  • Cryo-Cell avoided a delisting scare for now, but investors still face a 2027 countdown
  • Ensoma’s EN-374 safety data open a new test for in vivo HSC engineering
  • Why bioAffinity’s CyPath Lung growth still leaves investors facing a hard cash question
  • Can Kanvas Biosciences turn microbiome replacement into a maternal health intervention?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes